Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy

International Journal of Cardiology

Volumn 168, Issue 5, 2013, Pages 4624-4630

  Sverdlov, Aaron L ^a   Chan, Wai P A ^a   Procter, Nathan E K ^a   Chirkov, Yuliy Y ^a   Ngo, Doan T M ^a   Horowitz, John D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

ACE inhibitors; Aging; Nitric oxide; Platelets; Thioredoxin interacting protein

Indexed keywords

GUANYLATE CYCLASE; NITRIC OXIDE; RAMIPRIL; THIOREDOXIN INTERACTING PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; THROMBOCYTE;

ACE INHIBITORS; AGING; NITRIC OXIDE; PLATELETS; THIOREDOXIN-INTERACTING PROTEIN;

ADULT; AGED; AGING; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PLATELETS; BLOTTING, WESTERN; CARRIER PROTEINS; FEMALE; FOLLOW-UP STUDIES; GUANYLATE CYCLASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NITRIC OXIDE; RAMIPRIL; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84886412163     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.159     Document Type: Article

References (65)

1. Y.Y. Chirkov, and J.D. Horowitz Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther 116 2007 287 305
2. S.R. Willoughby, S. Stewart, A.S. Holmes, Y.Y. Chirkov, and J.D. Horowitz Platelet nitric oxide responsiveness: a novel prognostic marker in acute coronary syndromes Arterioscler Thromb Vasc Biol 25 2005 2661 2666
3. M.I. Worthley, A.S. Holmes, and S.R. Willoughby The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration J Am Coll Cardiol 49 2007 304 310
4. S.R. Willoughby, S. Rajendran, and W.P. Chan Ramipril sensitizes platelets to nitric oxide: implications for therapy in high-risk patients J Am Coll Cardiol 60 10 2012 887 894
5. Y.Y. Chirkov, A.S. Holmes, L.P. Chirkova, and J.D. Horowitz Nitrate resistance in platelets from patients with stable angina pectoris Circulation 100 1999 129 134
6. J. Nordberg, and E.S. Arner Reactive oxygen species, antioxidants, and the mammalian thioredoxin system Free Radic Biol Med 31 2001 1287 1312
7. M. Miyamoto, C. Kishimoto, M. Nimata, H. Nakamura, and J. Yodoi Thioredoxin, a redox-regulating protein, is expressed in spontaneous myocarditis in inbred strains of mice Int J Cardiol 95 2004 315 319
8. H. Masutani, K. Hirota, and T. Sasada Transactivation of an inducible anti-oxidative stress protein, human thioredoxin by HTLV-I Tax Immunol Lett 54 1996 67 71
9. S.W. Kang, H.Z. Chae, M.S. Seo, K. Kim, I.C. Baines, and S.G. Rhee Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha J Biol Chem 273 1998 6297 6302
10. J. Haendeler, J. Hoffmann, V. Tischler, B.C. Berk, A.M. Zeiher, and S. Dimmeler Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69 Nat Cell Biol 4 2002 743 749
11. R. Bertini, O.M. Howard, and H.F. Dong Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells J Exp Med 189 1999 1783 1789
12. M. Yamamoto, G. Yang, and C. Hong Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy J Clin Invest 112 2003 1395 1406
13. A. Nishiyama, M. Matsui, and S. Iwata Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression J Biol Chem 274 1999 21645 21650
14. S.H. Han, J.H. Jeon, and H.R. Ju VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression Oncogene 22 2003 4035 4046
15. P.C. Schulze, J. Yoshioka, T. Takahashi, Z. He, G.L. King, and R.T. Lee Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein J Biol Chem 279 2004 30369 30374
16. H. Parikh, E. Carlsson, and W.A. Chutkow TXNIP regulates peripheral glucose metabolism in humans PLoS Med 4 2007 e158
17. L. Perrone, T.S. Devi, K. Hosoya, T. Terasaki, and L.P. Singh Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions J Cell Physiol 221 2009 262 272
18. G. Powis, D. Mustacich, and A. Coon The role of the redox protein thioredoxin in cell growth and cancer Free Radic Biol Med 29 2000 312 322
19. S. Yoshida, T. Katoh, T. Tetsuka, K. Uno, N. Matsui, and T. Okamoto Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts J Immunol 163 1999 351 358
20. P. Patwari, W.A. Chutkow, and K. Cummings Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins J Biol Chem 284 2009 24996 25003
21. H. Yamawaki, S. Pan, R.T. Lee, and B.C. Berk Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells J Clin Invest 115 2005 733 738
22. K.A. Robinson, J.W. Brock, and M.G. Buse Posttranslational regulation of thioredoxin-interacting protein J Mol Endocrinol 50 2012 59 71
23. T. Yoshida, N. Kondo, and S. Oka Thioredoxin-binding protein-2 (TBP-2): its potential roles in the aging process Biofactors 27 2006 47 51
24. W.P. Chan, D.T. Ngo, and A.L. Sverdlov Premature aging of cardiovascular/platelet function in polycystic ovarian syndrome Am J Med 126 7 2013 640.e1 640.e7
25. P.C. Schulze, H. Liu, and E. Choe Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity Arterioscler Thromb Vasc Biol 26 2006 2666 2672
26. D.T. Ngo, I. Stafford, and A.L. Sverdlov Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations Br J Pharmacol 162 2011 722 732
27. J.F. Grant, A.W. Taylor, and R.E. Ruffin Cohort profile: the North West Adelaide Health Study (NWAHS) Int J Epidemiol 38 2009 1479 1486
28. A.L. Sverdlov, D.T. Ngo, and W.P. Chan Determinants of aortic sclerosis progression: implications regarding impairment of nitric oxide signalling and potential therapeutics Eur Heart J 33 2012 2419 2425
29. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
30. Y.Y. Chirkov, L.P. Chirkova, and J.D. Horowitz Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris Naunyn Schmiedebergs Arch Pharmacol 354 1996 520 525
31. M. Shaked, M. Ketzinel-Gilad, E. Cerasi, N. Kaiser, and G. Leibowitz AMP-activated protein kinase (AMPK) mediates nutrient regulation of thioredoxin-interacting protein (TXNIP) in pancreatic beta-cells PLoS One 6 2011 e28804
32. J. Chen, H. Cha-Molstad, A. Szabo, and A. Shalev Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein Am J Physiol Endocrinol Metab 296 2009 E1133 E1139
33. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp Thioredoxin-interacting protein links oxidative stress to inflammasome activation Nat Immunol 11 2010 136 140
34. Koenen TB, Stienstra R, van Tits LJ, et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue. Diabetes.60:517-24.
35. X. Li, Y. Rong, and M. Zhang Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells Biochem Biophys Res Commun 381 2009 660 665
36. J. Yoshioka, W.A. Chutkow, and S. Lee Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury J Clin Invest 122 2012 267 279
37. W.P. Castelli Epidemiology of coronary heart disease: the Framingham study Am J Med 76 1984 4 12
38. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science.327:296-300.
39. F. Turturro, E. Friday, and T. Welbourne Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231 BMC Cancer 7 2007 96
40. K.S. Chen, and H.F. DeLuca Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3 Biochim Biophys Acta 1219 1994 26 32
41. M. Rakhshandehroo, L.M. Sanderson, and M. Matilainen Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling PPAR Res 2007 2007 26839
42. S. Oka, H. Masutani, and W. Liu Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling Endocrinology 147 2006 733 743
43. K.Y. Kim, S.M. Shin, J.K. Kim, S.G. Paik, Y. Yang, and I. Choi Heat shock factor regulates VDUP1 gene expression Biochem Biophys Res Commun 315 2004 369 375
44. P.C. Schulze, G.W. De Keulenaer, J. Yoshioka, K.A. Kassik, and R.T. Lee Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin Circ Res 91 2002 689 695
45. E. Wu, N. Palmer, and Z. Tian Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells PLoS One 3 2008 e3794
46. C. Tziros, and J.E. Freedman The many antithrombotic actions of nitric oxide Curr Drug Targets 7 2006 1243 1251
47. Y.Y. Chirkov, A.S. Holmes, and S.R. Willoughby Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets J Am Coll Cardiol 37 2001 1851 1857
48. Y.Y. Chirkov, M. De Sciscio, A.L. Sverdlov, S. Leslie, P.R. Sage, and J.D. Horowitz Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure Cardiovasc Drugs Ther 24 2010 131 137
49. Y.Y. Chirkov, A.S. Holmes, J.D. Martelli, and J.D. Horowitz Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction Am J Cardiol 93 2004 1438 1440 [A10]
50. R.A. Anderson, G.R. Ellis, and Y.Y. Chirkov Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure Eur J Heart Fail 6 2004 47 54
51. G.R. Ellis, R.A. Anderson, and Y.Y. Chirkov Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure J Cardiovasc Pharmacol 37 2001 564 570
52. R.A. Anderson, G.R. Ellis, and L.M. Evans Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes Diab Vasc Dis Res 2 2005 88 93
53. G. Anfossi, E.M. Mularoni, and S. Burzacca Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM Diabetes Care 21 1998 121 126
54. J.M. Stepien, R.M. Prideaux, S.R. Willoughby, Y.Y. Chirkov, and J.D. Horowitz Pilot study examining the effect of cholesterol lowering on platelet nitric oxide responsiveness and arterial stiffness in subjects with isolated mild hypercholesterolaemia Clin Exp Pharmacol Physiol 30 2003 507 512
55. J.D. Woods, J.S. Edwards, and J.M. Ritter Inhibition by nitroprusside of platelet calcium mobilization: evidence for reduced sensitivity to nitric oxide in essential hypertension J Hypertens 11 1993 1369 1373
56. Y.Y. Chirkov, K. Mishra, S. Chandy, A.S. Holmes, R. Kanna, and J.D. Horowitz Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic stenosis J Heart Valve Dis 15 2006 28 33
57. M. Shaked, M. Ketzinel-Gilad, Y. Ariav, E. Cerasi, N. Kaiser, and G. Leibowitz Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets Diabetologia 52 2009 636 644
58. G. Xu, J. Chen, G. Jing, and A. Shalev Preventing beta-cell loss and diabetes with calcium channel blockers Diabetes 61 2012 848 856
59. S. Yusuf Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) study Eur Heart J 22 2001 103 104
60. M.M. Patarroyo Aponte, and G.S. Francis Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in atherosclerosis prevention Curr Cardiol Rep 14 2012 433 442
61. O.N. Spindel, C. World, and B.C. Berk Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms Antioxid Redox Signal 16 2012 587 596
62. D.F. Mahmood, A. Abderrazak, K. El Hadri, T. Simmet, and M. Rouis The thioredoxin system as a therapeutic target in human health and disease Antioxid Redox Signal 2013 10.1089/ars.2012.4757
63. L. Perrone, T.S. Devi, K.I. Hosoya, T. Terasaki, and L.P. Singh Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy Cell Death Dis 1 2010 e65
64. P. Patwari, and R.T. Lee An expanded family of arrestins regulate metabolism Trends Endocrinol Metab 23 2012 216 222
65. J.C. Kovacic, P. Moreno, V. Hachinski, E.G. Nabel, and V. Fuster Cellular senescence, vascular disease, and aging: part 1 of a 2-part review Circulation 123 2011 1650 1660